收藏 分销(赏)

内科病人静脉血栓栓塞性疾病李小鹰.ppt

上传人:快乐****生活 文档编号:14606855 上传时间:2026-10-19 格式:PPT 页数:105 大小:1.29MB 下载积分:10 金币
下载 相关
内科病人静脉血栓栓塞性疾病李小鹰.ppt_第1页
第1页 / 共105页
内科病人静脉血栓栓塞性疾病李小鹰.ppt_第2页
第2页 / 共105页


点击查看更多>>
资源描述
Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,1,*,单击此处编辑母版标题样式,*,*,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,*,内科病人静脉血栓栓塞性疾病李小鹰,内科病人静脉血栓栓塞性疾病李小鹰内科病人静脉血栓栓塞性疾病李小鹰全面认识VTE全球VTE的发生率居高不下,VTE是患者死亡的主要因素,VTE带来沉重的负荷,多数VTE的发生与入院时存在的基础疾病和手术情况相关,院内或院外适宜的静脉血栓预防可降低VTE所带来的危害。VTE 是可预防的严峻的公共卫生保健问题,全面认识,VTE,全球,VTE,的发生率居高不下,VTE,是患者死亡的主要因素,VTE,带来沉重的负荷,多数,VTE,的发生与入院时存在的基础疾病和手术情况相关,院内或院外,适宜的,静脉血栓预防可降低,VTE,所带来的危害,。,VTE,是,可预防的严峻的公共卫生保健问题,1,Cohen AT.Presented at the 5th Annual Congress of the European Federation of Internal Medicine;2005.,2,Eurostat statistics on health and safety 2001.,Available from:epp.eurostat.cec.eu.int.,VTE,所致死亡触目惊心,VTE,所导致的死亡例数,:543,454,1,(,2005,第,5,欧盟内科年会),VTE,所致死亡超过了以下原因所致死亡的总数,:,AIDS,5,860,2,乳腺癌,86,831,2,前列腺癌,63,636,2,交通事故,53,599,2,2006,年中国住院患者,PTE,死亡率达,9.74%,内科患者,VTE,:一个被低估的全球疾病负担,住院人群统计,死亡者中,10%,死于,PTE,1,PTE,死亡者中,,75%,合并有内科疾病,2,住院期间,17%,的重症患者发生症状性,DVT,3,75%,的内科重症患者存在,2,个以上,VTE,的危险因素,4,1.Sandler DA et al.,J R Soc Med,1989;82:203-5.,2.Baglin TP et al.,J Clin Pathol,1997;50:60910.,3.Mismetti P et al.,Thromb Haemost,2000;83:149.,4.Anderson FA et al.,J Vasc Surg,1992;19:557-8,内科住院患者,VTE,患病率,未经治疗时,DVT,的危险性,0%,1,2,%,22%,2,8,33,%,30,5,0%,内科,脑卒中偏瘫,ICU,AMI,1.Leizorovicz and Mismetti.,Circulation,2004;110(Suppl IV):139.,2.Fraisse F,et al.,Am J Respir Crit Care Med.,2000.161:1109-1114.,3.,Spyropoulos AC,et al,.,Chest,2005.128:958-969.,4.,Cohen AT,et al.,Thromb Haemost 2005.94:750-759.,内科住院患者,VTE,患病率国外前瞻性研究,1.Samama MM et al.,N Engl J Med,1999;341:793800.2.Leizorovicz A et al.,Circulation,2004;110:87479.,3.Cohen AT et al.,BMJ,2005;in press.,致死性,PE,DVT,所有致死性,PE,病例在死亡,前得到诊断的不足一半,1,约,80%DVT,病例无临床表现,2,3,VTE,经常得不到及时诊断,1.Goldhaber SZ,et al.American Journal of Medicine 1982;73:822-826.,2.Lethen H,et al.,American Journal of Cardiology 1997;80:1066-1069.3.Sandler DA,et al.J.Royal Soc.Med.1989;82:203-205.,住院接受内科治疗的患者属于,VTE,高危人群,静脉血流缓慢,血管内皮受损,极高危,中,/,高危,低,/,中危,高凝状态,中国,PTE,发病并不少见,全国,PTE-DVT,形成防治协作组报道的,PTE,病例数,(年),老年内科住院患者,VTE,事件,发生率调查,VTE,in,C,linical,M,edical,E,lderly,P,atients,(,VTE-CMEP,),VTE-CMEP,研究,VTE-CMEP,研究方案,0,天,14-21,天,90,天,入选老年内科急症,住院患者,607,例,首次随访,CUS,二次随访,VTE,事件,,CUS,三次随访,电话,VTE,事件,VTE-CMEP,主要终点事件,主要终点事件,90,天内客观检查证实的,DVT,;,90,天内客观检查证实的致死性或非致死性,PE,;,客观检查证实的无症状的,DVT,。,次要终点事件,90,天内全因死亡。,入选患者基础疾病情况,%,心力衰竭,60.6%,代谢性疾病,42.0%,内脏炎症,29.9%,慢性肾功能不全,26.5%,急性冠脉综合症,24.5%,急性脑梗塞,10.5%,呼吸衰竭,10.0%,恶性肿瘤,5.9%,VTE,病史,3.8%,VTE-CMEP,主要终点事件,主要终点患病 率(),9.7%,0,1.5,3,4.5,6,7.5,9,VTE,事件,7.3%,2.1%,DVT,PE,DVT+PE,0.5%,内科急症不同患者,VTE,的发生率,COPD,伴急性呼吸衰竭,18.8%,呼吸衰竭,16.4%,急性脑梗塞,15.6%,急性感染性疾病,14.3%,急性冠脉综合症,8.7%,心力衰竭,7.6%,急性心肌梗死,4.2%,不同基础疾病,VTE,发生率,VTE,史,34.8%,静脉曲张,20.5%,慢性内脏炎症疾病,14.3%,恶性肿瘤,11.1%,肥胖,10.7%,慢性肾功能不全,8.7%,代谢疾病,8.2%,不同治疗措施患者,VTE,发生率,呼吸衰竭伴机械通气,23.5%,中心静脉导管,18.9%,永久性起搏器,17.6%,VTECMEP,与其他研究结果比较,0,2,4,6,8,10,12,14,16,MEDENOX,PREVENT,CMEP,VTE,发病率(),4.96%,14.9%,9.7%,ARTEMIS,10.5%,内科高危患者接受,VTE,预防不足,IMPROVE,研究:,1500,例内科高危患者,39,ENDORSE,研究:,37356,例内科高危患者,40,国内(,CMEP,与,RAMP,)研究,1854,例内科高危患者,20,VTE-CMEP,研究预防,VTE,治疗情况,项目 首次随访 二次随访 末次随访,抗凝药物,普通肝素,13.0%6.0%0.9%,低分子肝素,7.1%3.0%0,华法令,5.4%6.8%4.0%,机械性预防,弹力袜,0 0.3%0.2%,下肢循环驱动器,0 0 0,肢体按摩,0 4.0%1.4%,VTE-RAMP,研究,ICU/CCU,内科急症住院患者,VTE,风险评估和预防治疗现况调查,(,VTE,R,isk Assessment and Prophylaxis Treatment among,A,cute,M,edical,P,atients in ICU/CCU in China A cross-sectional Survey,),ICU vs CCU,符合标准病人入组情况,(,N,=,1247,),CCU,(N=704),ICU,(N=543),内科重症患者,VTE,危险因素比例,评估的患者中,有,99.0%,的患者采用血栓预防治疗后受益的证据,其中,57.8%,患者有多重危险因素,危险因素个数,接受,ACCP,指南推荐的预防措施的比例*,*ACCP,指南推荐的内科重症患者的预防方法包括:,无药物预防禁忌患者使用普通肝素或低分子肝素;,有药物预防禁忌患者使用机械预防方法(弹力袜或充气加压装置),ENDORSE,研究,-,急症住院,VTE,危险患者流行病学国际评估研究,ENDORSE-E,pidemiologic,Inter,N,ational,D,ay,for the,Evaluati,O,n,of Patients at,R,isk of Venous Thrombosis in the Acute Hospital Care,Se,tting,外科及内科患者所占比例,(,N,=,68,183,),外科患者,(N=30,827),内科患者,(N=37,356),主要研究目的,42,%,存在,VTE,危险,内科患者,(,n,=,37,356,),次要研究目的,40,%,接受了,ACCP,治疗推荐,64,%,存在,VTE,危险,59,%,接受了,ACCP,推荐治疗,外科患者,(n,=30,827,),内科,VTE,高危并接受推荐预防治疗的患者,52,%,存在,VTE,危险,50,%,接受了,ACCP,推荐治疗,总计,(,N=68,183,),内外科,VTE,高危患者接受推荐预防治疗情况,外科患者,内科患者,88,82,66,59,47,髋,/,膝关节置换,髋部骨折,胃部疾病,结肠疾病,泌尿系统疾病,45,41,40,25,急性呼吸系统疾病,急性心衰,肺部感染,缺血性卒中,0,25,50,75,100%,0,25,50,75,100%,内科住院患者,VTE,机械性预防,机械性预防措施,分级加压弹力袜,(,GCS,),间歇充气加压泵,(,IPC,),足底静脉泵,(,VFP,),缺血性脑卒中患者应用,10 d,后经超声诊断的,DVT,发生率,GCS+IPC,预防组为,4.7%,单用,GCS,预防组为,15.9%,Lacut K,et al.Neurology,2005.,65,:865-869,内科,VTE,药物预防疗效,低剂量普通肝素(,LDUH,),低分子肝素(,LMWH,),MEDENOX,PREVENT,PRINCE,PRINCE-II,磺达肝癸钠,ARTEMIS,使用肝素进行血栓预防治疗可显著获益,0,1,2,3,4,5,相对危险性,肝素较好,肝素较差,Belch 1981,Dahan 1986,Ibara-Perez 1988,Bergmann 1996,Gardlund 1996,Fraisse 1998,总,PE,Mismetti P,et al.Thromb Haemost 2000;83:14-19.,RR=0.480.34-0.68,P0.001,方差分析:,P=NS,低分子肝素杰出的疗效进一步被证实,几项较大的研究结果显示,低分子肝素预防,内科住院患者,VTE,显著优于安慰剂,研究,病例数,药物治疗,VTE,发病率,OR,95%CI,NNT,P,MEDENOX,1102,依诺肝素,20mg,qd,14,天,40mg,qd,14,天,5.5,0.37,0.22-0.63,9,例,0.001,安慰剂,14,天,14.9,PREVENT,3681,达肝素,5000IU,qd,14,天,2.6,0.55,0.38-0.80,45,例,=0.002,安慰剂,14,天,5.0,ARTEMIS,849,Fondparinux 2.5mg,qd,14,天,1.5,0.53,0.31-0.92,=0.085,安慰剂,3.4,NNT:,每挽救,1,例,VTE,所需要治疗的病人数,0,4,8,12,16,所有 静脉栓塞事件,所有近端 的深静脉血栓事件,安慰剂,(n=288),依诺肝素,40 mg(n=291),P,=0.037,P,=0.0002,NS,患者,(%),DVT,深静脉血栓,;PE,肺栓塞,NS,无显著意义,;VTE,静脉血栓栓塞,;,RRR,相对风险降低,RRR 63%,依诺肝素,4000 AXa IU,使近端,DVT,风险降低,65,,此益处在,3,个月随访时仍然存在,RRR 65%,14,天治疗期间的静脉血栓栓塞性事件:,Medenox,研究:患者随机分组,分别接受依诺肝素,20,毫克或依诺肝素,40,毫克治疗,或者给予安慰剂,接受依诺肝素,20mg,治疗的患者与接受安慰剂治疗的患者相比,其预后没有显示显著差异。,Samama et al.A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients,.Prophylaxis in Medical Patients with Enoxaparin Study Group.N Engl J Med 1999;341:793-800,MEDENOX,研究,PREVENT,研究结果,21,天时,达肝素(法安明)显著降低主要终点发生率达,45,主要终点:,DVT/PE/,猝死,法安明,5000IU,组,安慰剂组,主要终点发病 率(),2.77%,4.96%,0,1,2,3,4,5,45,P=0.0015,Leizorovicz A,et al.Circulation 2004;110:874-879.,内科治疗病人预防静脉血栓形成,依诺肝素是唯一一种,LMWH,已经在国内外注册用于预防内科治疗患者的静脉血栓形成,MEDENOX,n,=1102,1,PRINCE,n,=451,2,PRINCE II,n,=206,3,0,2,4,6,8,10,12,14,16,VTE;,第,1-14,天,(%),P,0.001,0,2,4,6,8,10,12,VTE(%),0,2,4,6,8,10,12,14,16,18,VTE(%),0,5,10,15,20,25,30,35,40,VTE (%),P,=0.015,等效性检验,A,P,=0.014,等效性检验,A,P,=0.044,依诺肝素,40 mg,(4000 IU,抗,Xa)qd,依诺肝素,20 mg,(2000 IU,抗,Xa)qd,安慰剂,qd,肝素钙,5000 IU s.c.tid,VTE,venous thromboembolic events,LMWH,low-molecular-weight heparin,1.Samama MM,et al.,N Engl J Med,1999;341:793-800.,2.Kleber et al.,Thromb Haemost,1999;(suppl)1552.,3.Kleber et al.,Unpublished Data,A.,等效性检验:两种治疗等效,等效的定义是两组的最大差异为,4%,低分子肝素与普通肝素疗效比较,普通肝素更好,低分子肝素更好,DVT,PE,死亡,大出血,P=NS,P=NS,P=NS,P=0.049,0,1,2,相对危险性,Mismetti P,et al.Thromb Haemost 2000;83:14-19.,内科住院患者静脉血栓栓塞症预防中国专家建议写作组中华医学会老年医学分会中华医学会呼吸病学分会中华老年医学杂志编辑委员会中华结核和呼吸杂志编辑委员会,中华老年医学杂志 中华呼吸结核杂志,2009,年第一期,内科住院患者静脉血栓栓塞症预防中国专家建议,中国专家建议预防性治疗的指征与方法,一、需要进行,VTE,预防性治疗的内科患者,二、,VTE,预防性治疗的方法,(一)机械性预防措施,(二)药物预防性治疗,三、一些特殊临床情况下的,VTE,预防性治疗,、,急性心肌梗死,、,急性脑卒中,、,重症监护病房(,ICU,)患者,、,恶性肿瘤,、,肾功能不全,四、几点说明,需要进行,VTE,预防性治疗的内科患者,For acutely ill medical patients admitted to hospital with,congestive heart failure,or,severe respiratory disease,or,who are confined to bed,and,have one or more additional risk factors,active cancer,previous VTE,sepsis,acute neurologic disease,or inflammatory bowel disease,ACCP 8,th,Edition guidelines,需要进行,VTE,预防性治疗的内科患者,国内专家建议,40,岁以上因急性内科疾病住院患者,,和,卧床,3d,,,同时,合并下列病症或危险因素之一,呼吸衰竭、,COPD,急性加重、急性脑梗死、心力衰竭(,NYHA,或,级)、急性感染性疾病(重症感染或感染中毒症)、急性冠状动脉综合征、,VTE,病史、恶性肿瘤、炎性肠病、慢性肾脏疾病、下肢静脉曲张、,肥胖(体重指数,30 kg,m,)及高龄(年龄,75,岁)。,VTE,预防性治疗的方法,机械性预防措施,适应证,无机械预防性治疗禁忌证的,VTE,高危患者,,建议与药物预防联合应用,对抗凝药物治疗有禁忌证的,VTE,高危患者,出血性脑卒中或缺血性脑卒中,抗凝治疗弊大于利的患者,患肢无法或不宜应用机械性预防措施者可在对侧实施预防,VTE,预防性治疗的方法,机械性预防措施,禁忌证,严重下肢动脉硬化性缺血,充血性心力衰竭,肺水肿,下肢,DVT,(,GCS,除外),血栓性静脉炎,下肢局部严重病变(,皮炎、坏疽、近期手术及严重畸形),VTE,预防性治疗的方法,药物预防性治疗,单独应用阿司匹林无助于预防,VTE,LDUH,方法:,5000 U,,,SC,,,1,次,12 h,,,6-14 d,禁忌证,:,出血性疾病,凝血功能障碍,外伤与术后渗血,先兆流产,恶性高血压,细菌性心内膜炎,对肝素过敏者,VTE,预防性治疗的方法,LDUH,应用中需要特别重视的几个问题,密切观察出血并发症和严重出血危险,发生出血,立即停用肝素,可静脉注射硫酸鱼精蛋白(,1mg,100 U,肝素),对高危人群监测,APTT,以调整剂量,年龄,75,岁,肾功能不全,进展期肿瘤,监测血小板计数,警惕,HIT,VTE,预防性治疗的方法,LMWH,使用方法,依诺肝素,40mg,,,1,次,d,达肝素,5000 U,,,1,次,d,疗程:,6-14 d,禁忌证,对,LMWH,过敏,其余禁忌证同普通肝素,磺达肝癸钠,2.5 mg,,,1,次,d,,建议治疗,6,14d,住院患者血栓预防治疗流程,患者是否属于,高危人群,是,患者是否无法接受药物性血栓预防,开始血栓预防治疗:法安明,5000IU/,依诺肝素,4000IU 1/d,或普通肝素,5000IU 1/12h,血栓预防治疗一般需要维持,6-14,天,同时应考虑其他临床因素或住院时间的长短以确定血栓预防的疗程,随着病情的变化,对可能导致静脉血栓栓塞性疾病的危险因素进行重新评估,考虑非药物血栓预防方法,如弹力袜,间歇式气压治疗仪,足底泵,否,否,是,一些特殊临床情况下,VTE,预防性治疗,急性心肌梗死(,AMI,),无需常规用药预防,VTE,经评估,VTE,高危的,AMI,患者,如无禁忌证,可延长,LMWH,治疗时间至周,延长治疗期间改为预防剂量,可联合使用机械性预防措施,一些特殊临床情况下,VTE,预防性治疗,急性脑卒中,缺血性脑卒中,无禁忌证,给予,LDUH,或,LMWH,用药前必须仔细权衡血栓和出血的风险,建议联合机械性预防措施预防,VTE,出血性脑卒中,如无禁忌证,应使用机械性预防措施预防,VTE,一些特殊临床情况下,VTE,预防性治疗,ICU,患者,无禁忌证,使用,LDUH,或,LMWH,进行预防,并建议联合应用机械方法预防,VTE,;,有高出血风险的患者,先采取,GCS,和(或),IPC,预防血栓直至出血风险降低,然后用药物代替机械方法预防血栓,或药物与机械方法联合应用;,对药物和机械预防措施均有禁忌证的患者,应加强临床监护和床旁超声检查,以尽早发现和治疗,VTE,一些特殊临床情况下,VTE,预防性治疗,恶性肿瘤,因内科急症住院的,VTE,高危恶性肿瘤患者,建议常规给予血栓预防性治疗,行化疗或糖皮质激素治疗的恶性肿瘤患者,不建议常规使用血栓预防性治疗,进展期乳腺癌接受化疗者,可考虑应用低剂量华法林预防性治疗,置有中心静脉导管的恶性肿瘤患者,不推荐常规使用药物预防血栓形成,一些特殊临床情况下,VTE,预防性治疗,肾功能不全,对严重肾功能不全的患者,建议选择,LDUH,作为预防性抗凝治疗的药物,肌酐清除率,30 ml,min,的患者,如选择,LMWH,,建议减量使用,应用,LMWH,时,如有条件,建议每,1,2,天监测凝血因子,Xa,水平,据此调整剂,附一:肝素诱导的血小板减少症,(,略,),附二:内科患者静脉血栓栓塞症治疗原则,(,略,),谢谢!,53,54,Prevalence and Prevention of Venous Thromboembolism,in Medical Patients,Li Xiao Ying,MD,Chinese PLA General Hospital,BEIJING,CHINA,55,Clinical Review of Venous Thromboembolism,The incidence of venous,t,hromboemboli,sm(VTE)is,increasing,VTE is,responsible for a large number of hospital deaths,VTE is a heavy burden globally,The majority of VTE is associated with underlying,disorders and surgical conditions,Appropriate,thromboprophylaxis has been shown to be,effective and safe for most VTE patients,A big challenge for public health and health care,1,Cohen AT.Presented at the 5th Annual Congress of the European Federation of Internal Medicine;2005.,2,Eurostat statistics on health and safety 2001.,Available from:epp.eurostat.cec.eu.int.,The Shocking,M,ortality,of,VTE,VTE causes 543,454 death in hospital yearly,More than combined total of deaths from AIDS,breast,cancer,prostatic carcinoma and traffic accidents,AIDS,5,860,breast cancer,86,831,prostatic carcinoma,63,636,traffic accidents,53,599,9.74%of hospitalized Chinese patients died from,pulmonary thromboembolism,(,PET)in 2006,An,Underestimate Burden in the World,10%,of,hospitalized patients die from PTE,1,75%,of dead cases have a complication of medical disorders,2,17%,of,severe hospitalized patients develop,symptomatic,DVT,3,75%,of,hospitalized patients with acute medical illness,have above,two VTE,r,isk factors,4,1.Sandler DA et al.J R Soc Med,.,1989,82:203-,20,5.,2.Baglin TP et al.J Clin Pathol,.,1997,50:609,-6,10.,3.Mismetti P et al.Thromb Haemost,.,2000,83:14,-1,9.,4.Anderson FA et al.J Vasc Surg,.,1992,19:557,-55,8,The Risk for VTE in Medical Hospitalized Patients,Risk of VTE with no prophylaxis in various groups of hospitalized patients,0,%,1,2,%,22%,2,8,33,%,30,5,0%,Internal Medicine,Acute Ischemic Stroke,ICU,AMI,1.Leizorovicz and Mismetti.Circulation.,2004,110(Suppl IV):13,-1,9.,2.Fraisse F,et al.,Am J Respir Crit Care Med.2000,161:1109-1114.,3.,Spyropoulos AC,et al,.Chest,.,2005,128:958-969.,4.,Cohen AT,et al.,Thromb Haemost.2005,94:750-759.,59,The Incidence of VTE,in Medical Hospitalized Patients,1.Samama MM et al.N Engl J Med.1999,341:79-3800.,2.Leizorovicz A et al.Circulation.2004,110:874-879.,3.Cohen AT et al.BMJ.2005,in press.,60,fatal,PE,DVT,Pre-death diagnosis was made,in less than 50%of fatal PE,About 80%of DVT,presents,with asymptomatic,Timely D,iagnosis,of VTE is Very Important,1.Goldhaber SZ,et al.American Journal of Medicine 1982;73:822-826.,2.Lethen H,et al.,American Journal of Cardiology 1997;80:1066-1069.,3.Sandler DA,et al.J.Royal Soc.Med.1989;82:203-205.,61,Medical Hospitalized Patients,High Risk Population to Develop VTE,venous stasis,endothelial,injury,Very high risk,Moderate/high risk,Low/moderate risk,hypercoaguability,62,The Incidence of PET in China,Time,PET Incidence,the collaboration group on PTE-DVT prevention and treatment in China,VTE-CMEP,study in China,VTE,in,C,linical,M,edical,E,lderly,P,atients,64,Design of VTE-CMEP,0 days,14-21days,90 days,A total of 607 acutely ill medical hospitalized elderly,patients,were enrolled,1,st,follow-up,2,nd,follow-up,last follow-up,CUS*,CUS,VTE event,telephone,VTE event,*CUS:c,ompressed ultrasound,65,End Points of VTE-CMEP,Primary end points(within 90 day-follow up period),Objectively verified DVT,Objectively verified fatal and non-fatal PE,Objectively verified asymptomatic DVT,Secondary end points(within 90 day-follow up period),A,ll-cause mortality,66,Baseline,Characteristics,of t,he,Patients,Heart failure 60.6%,Metabolic disease,42.0%,Visceral,i,nflammation,29.9%,Chronic renal insufficiency 26.5%,Acute coronary syndrome 24.5%,Acute brain infarction,10.5%,Respiratory failure 10.0%,M,alignant tumor,5.9%,VTE history 3.8%,67,Primary End Points of,VTE-CMEP,Primary end points,(),9.7%,0,1.5,3,4.5,6,7.5,9,VTE,7.3%,2.1%,DVT,PE,DVT+PE,0.5%,68,VTE,Incidence,in,Patients,with Acute illness,COPD with respiratory failure 18.8%,Respiratory failure 16.4%,Acute stroke 15.6%,Acutely infectious diseases,14.3%,Acute coronary syndrome 8.7%,Heart failure 7.6%,Acute myocardial infarction,4.2%,69,History of VTE,34.8%,V,aricosis,20.5%,Chronic,Visceral,Inflammation,14.3%,Malignant tumour 11.1%,O,besity,10.7%,Chronic renal insufficiency 8.7%,Metabolic disease,8.2%,VTE Incidence in Patients with Underlying,D,isorders,70,Respiratory failure with mechanical ventilation,23.5%,C,entral venous catheter,18.9%,Permanent pacemaker,17.6%,VTE Incidence in Patients Who Accepted,Therapeutic Measures,71,The Comparison of VTE-CMEP with the International Prospective Studies,0,2,4,6,8,10,12,14,16,MEDENOX,PREVENT,CMEP,VTE incidence,(),4.96%,14.9%,9.7%,ARTEMIS,10.5%,72,The Percentage of VTE High Risk Medical Patients Accepted Prophylaxes Treatment,IMPROVE study,39,of,1,500 VTE high risk medical patients,ENDORSE study,40,of,37,356 VTE high risk medical patients,CMEP study and RAMP study in China,20,of 1,854 VTE high risk medical patients,73,Pharmacologic,al,and Mechanical Prophylaxis,Treatment in VTE-CMEP,Items 1,st,follow-up 2,nd,follow-up last follow-up,Anticoagulants,LDUH,13.0%6.0%0.9%,LMWH,7.1%3.0%0,Warfarin 5.4%6.8%4.0%,Mechanical Prophylaxis,Compression,Stockings,0 0.3%0.2%,Pneumatic,Compression,0 0 0,Limb Massage,0 4.0%1.4%,74,VTE-RAMP study,VTE,-,R,isk Assessment and Prophylaxis Treatment among,A,cute,M,edical,P,atients in ICU/CCU in China A cross-sectional Survey,75,Patients in ICU or CCU,Qualified for the,Enrollment,Criteria in RAMP,CCU,(N=704),ICU,(N=543),(,Total=1247),76,The Percentage of VTE Risk Factors in,Severe Medical Hospitalized Patients,99.0%of patients benefited from effective prophylaxes against embolism.,57.8%,of patients had,multiple,VTE risk factors,The number of VTE risk factors,ICU=543,CCU=704,Total=1247,%,77,The Percentage of Patients Accepted,Prophylaxis,Recommendations,by A,CCP,ACCP,recommendations for severe medical patients,LDUH,or,LMWH,for patients who have no contraindications to anticoagulant therapy,Mechanical prophylaxis(Compression,Stockings,or,Pneumatic,Compression,)for patients who have contraindications to anticoagulant therapy,78,E,p
展开阅读全文

开通  VIP、SVIP  下载更划算
下载10份以上建议开通 VIP 会员
下载20份以上建议开通SVIP会员


开通VIP      成为共赢上传

当前位置:首页 > 行业资料 > 医学/心理学

移动网页_全站_页脚广告1

关于我们      便捷服务       自信AI       AI导航        关注我们

©2010-2026 宁波自信网络信息技术有限公司  版权所有

客服电话:0574-28810668  投诉电话:18658249818

gongan.png浙公网安备33021202000488号   

icp.png浙ICP备2021020529号-1  |  浙B2-20240490  

关注我们 :微信公众号    抖音    微博    LOFTER 

客服